核磁共振波谱法测定新冠病毒RNA 成分的二级结构

This webinar took place on September 30th 2020

Register to download slides & media

总览

抗击新冠病毒引起的全球大流行病是当前社会和科学面临的最大挑战。德国法兰克福大学核磁共振研究小组发起倡议,于2020年3月底成立了一个由30个小组组成的国际联盟。利用核磁共振波谱,他们正在针对所有与新冠病毒相关的蛋白质进行结构检测,而其中的RNA成分则正在形成新型药物的潜在靶点。 

此外,他们将用RNA和蛋白质来筛选一个片段数据库,这个片段库是为了便于后续化学操作而设计的。(在本次研讨会中)我们专注于本项目的RNA部分,还将介绍项目的生化背景、核磁共振分配策略,并展示我们的筛选结果。 

Speakers

Sergey Arzhantsev, Ph.D
Sergey Arzhantsev, Ph.D
Research Physicist at FDA
Sergey Arzhantsev is Research Physicist in the Office of Testing and Research at the Food and Drug Administration in St. Louis, MO. He joined the Food and Drug Administration in 2009 and maintains an active research program in state-of-the-art technologies for drug analysis to support quality assessments. He received Ph.D. in Physics from M. V. Lomonosov Moscow State University in Moscow, Russia. He subsequently performed research at the Institute for Molecular Science, Japan and the Pennsylvania State University. In his present position at the FDA, Dr. Arzhantsev utilizes spectroscopic methods to study the quality and stability of pharmaceutical and biotechnology products.
Adrian Davis, Ph.D
Adrian Davis, Ph.D
Data Integrity Lead; Pfizer
Adrian Davis is a team leader and Research Fellow in Analytical R&D at Pfizer’s research laboratories in Sandwich, UK. He has over 25 yrs. of R&D experience, and in recent years has led Data integrity activities for Pfizer’s Pharmaceutical Sciences organization, focusing on the laboratory operations supporting clinical manufacturing activities. He’s also part of a strategic leadership group that is implementing Digital Transformation within the R&D environment and is very interested in technologies that help to simplify a very diverse laboratory data landscape. Fun fact: Adrian’s first professional lecture was at a Bruker NMR user meeting in the early 1990s, and he still remembers being so nervous that he couldn’t eat any of the lavish lunch that was provided!